Literature DB >> 10706174

Possible role of catheters in Saccharomyces boulardii fungemia.

C Hennequin1, C Kauffmann-Lacroix, A Jobert, J P Viard, C Ricour, J L Jacquemin, P Berche.   

Abstract

Four cases of Saccharomyces boulardii fungemia, a very rare side effect of Saccharomyces boulardii therapy, are reported. The clinical impact of Saccharomyces boulardii infection appeared to be moderate. However, even though organ involvement was never demonstrated, septic shock with no other etiology was observed in one of our patients. All patients had an indwelling vascular catheter. Contamination of the air, environmental surfaces, and hands following the opening of a packet suggests that catheter contamination may have been a source of infection. To prevent catheter contamination it is recommended that packets or capsules of Saccharomyces boulardii be opened with gloves, outside the patient's room.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10706174     DOI: 10.1007/s100960050003

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  41 in total

Review 1.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Use of probiotics in gastrointestinal disorders: what to recommend?

Authors:  Elizabeth C Verna; Susan Lucak
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

3.  Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial.

Authors:  P Marteau; M Lémann; P Seksik; D Laharie; J F Colombel; Y Bouhnik; G Cadiot; J C Soulé; A Bourreille; E Metman; E Lerebours; F Carbonnel; J L Dupas; M Veyrac; B Coffin; J Moreau; V Abitbol; S Blum-Sperisen; J Y Mary
Journal:  Gut       Date:  2005-12-23       Impact factor: 23.059

4.  Genome-wide association analysis of clinical vs. nonclinical origin provides insights into Saccharomyces cerevisiae pathogenesis.

Authors:  L A H Muller; J E Lucas; D R Georgianna; J H McCusker
Journal:  Mol Ecol       Date:  2011-08-31       Impact factor: 6.185

Review 5.  Risk and safety of probiotics.

Authors:  Shira Doron; David R Snydman
Journal:  Clin Infect Dis       Date:  2015-05-15       Impact factor: 9.079

6.  Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains.

Authors:  C Hennequin; A Thierry; G F Richard; G Lecointre; H V Nguyen; C Gaillardin; B Dujon
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

Review 7.  Bugs or drugs: are probiotics safe for use in the critically ill?

Authors:  Lindsay M Urben; Jennifer Wiedmar; Erica Boettcher; Rodrigo Cavallazzi; Robert G Martindale; Stephen A McClave
Journal:  Curr Gastroenterol Rep       Date:  2014

8.  Typing of Saccharomyces cerevisiae clinical strains by using microsatellite sequence polymorphism.

Authors:  J Y Malgoire; S Bertout; F Renaud; J M Bastide; M Mallié
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

Review 9.  Potential uses of probiotics in clinical practice.

Authors:  Gregor Reid; Jana Jass; M Tom Sebulsky; John K McCormick
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

Review 10.  Probiotics, Photobiomodulation, and Disease Management: Controversies and Challenges.

Authors:  Laura Marinela Ailioaie; Gerhard Litscher
Journal:  Int J Mol Sci       Date:  2021-05-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.